KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Average (2016 - 2025)

Gilead Sciences' Equity Average history spans 17 years, with the latest figure at $22.0 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 16.85% year-over-year to $22.0 billion; the TTM value through Dec 2025 reached $22.0 billion, up 16.85%, while the annual FY2025 figure was $21.0 billion, 0.31% changed from the prior year.
  • Equity Average reached $22.0 billion in Q4 2025 per GILD's latest filing, up from $20.5 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $22.5 billion in Q4 2023 to a low of $17.8 billion in Q2 2024.
  • Average Equity Average over 5 years is $20.2 billion, with a median of $20.5 billion recorded in 2022.
  • The largest YoY upside for Equity Average was 19.17% in 2021 against a maximum downside of 17.05% in 2021.
  • A 5-year view of Equity Average shows it stood at $21.3 billion in 2021, then dropped by 0.63% to $21.1 billion in 2022, then increased by 6.45% to $22.5 billion in 2023, then dropped by 16.16% to $18.9 billion in 2024, then grew by 16.85% to $22.0 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Equity Average are $22.0 billion (Q4 2025), $20.5 billion (Q3 2025), and $19.3 billion (Q2 2025).